Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ARVN Arvinas > Detailed Quotes

ARVN Arvinas

Watchlist
36.715
-2.795-7.07%
Trading Session  12/06 15:56 ET
High
39.575
Open
39.400
Turnover
13.87M
Low
36.000
Pre Close
39.510
Volume
374.33K
Market Cap
1.95B
P/E(TTM)
Loss
52wk High
83.400
Shares
53.23M
P/E(Static)
Loss
52wk Low
34.900
Float Cap
1.49B
Bid/Ask %
0.00%
Historical High
108.465
Shs Float
40.70M
Volume Ratio
0.75
Historical Low
10.190
Dividend TTM
--
Div Yield TTM
--
P/B
3.14
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.92%
Amplitude
9.05%
Avg Price
37.061
Lot Size
1
Float Cap
1.49B
Bid/Ask %
0.00%
Historical High
108.465
Shs Float
40.70M
Volume Ratio
0.75
Historical Low
10.190
Dividend TTM
--
P/B
3.14
Dividend LFY
--
Turnover Ratio
0.92%
Amplitude
9.05%
Avg Price
37.061
Lot Size
1
Price Forecast

News

Comment

Sign in to post a comment

No comment yet

Company Overview More
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
CEO: Dr. John G. Houston, PhD
Market: NASDAQ
Listing Date: 09/27/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist